Fosun Pharma initiates A-share repurchase program

Shanghai Fosun Pharmaceutical Group (SSE: 600196) announced its first repurchase of A-shares through centralized bidding on March 26, 2025. This move follows the approval of the A-share repurchase plan on January 22, 2025, as part of a strategy for employee stock ownership, equity incentives, or convertible bonds. The company repurchased 812,800 A-shares, representing 0.0304% of its total share capital, for a total expenditure of approximately RMB 19.99 million (excluding transaction costs). The shares were bought at prices ranging from RMB 24.54 to RMB 24.66 per share. The repurchase is within the approved range of RMB 300 million to RMB 600 million. Fosun Pharma stated that it will continue to implement the repurchase plan based on market conditions and regulatory requirements.